Wilson S Colucci MD

Adult Congenital Heart Disease, Heart Failure & Transplantation

Professor of Medicine, Boston University

732 Harrison Ave3RD floorBoston, MA 02118
Phone+1 617-638-7490
Fax+1 617-414-8742

Dr. Colucci is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Colucci's full profile Already have an account?

Summary

Dr. Wilson Colucci is a cardiologist based in Boston, MA, specialized in Heart Failure. He completed his medical education at Boston University School of Medicine in 1975 and underwent residency and fellowship training at Brigham and Women's Hospital. He is a Professor of Medicine at Boston University School of Medicine and is the Chief Emeritus of the Cardiovascular Section at Boston Medical Center. Dr. Colucci's expertise encompasses general cardiology and heart failure. His extensive basic and translational research has frequently been published in reputable journals, including recent studies on SGLT2 inhibitors and their impact on cardiac function. He has been involved in numerous clinical trials of therapies for heart failure, including landmark studies of converting enzyme inhibitors and beta blockers. Dr. Colucci has been recognized with honors such as being named in Boston Magazine by Castle Connolly, elected as a member of The American Society for Clinical Investigation, and being a Fellow of the American College of Cardiology.

Education & Training

Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1980 - 1981
Mass General Brigham/Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1978 - 1980
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1975 - 1978
Boston University School of MedicineClass of 1975

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1979 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2011-2013
Elected Member The American Society for Clinical Investigation, 1988
Super Doctor SuperDoctors.com

Clinical Trials

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
COMPLETED
PHASE2

Publications & Presentations

PubMed

10 citations
Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model.
Tomas Baka, Jarrod Moore, Fuzhong Qin, Salva R Yurista, Aifeng Zhang
European Heart Journal. 2025-10-22
3 citations
SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gαq-mice.
Jordan M Chambers, Dominique Croteau, David R Pimentel, Adam C Gower, Marcello Panagia
Journal of Molecular and Cellular Cardiology Plus. 2025-06-01
18 citations
SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy.
Dominique Croteau, Tomas Baka, Sara Young, Huamei He, Jordan M Chambers
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023-04-01

Other

Calcium channel blockers in heart failure due to systolic dysfunction
Colucci WS
http://www.uptodate.com/contents/calcium-channel-blockers-in-heart-failure-due-to-systolic-dysfuncti
UpToDate, Wolters Kluwer Health - 2012-02-29
Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction
Colucci WS
http://www.uptodate.com/contents/rationale-for-and-clinical-trials-of-beta-blockers-in-heart-failure
UpToDate, Wolters Kluwer Health - 2012-10-16
Impact of anemia in patients with heart failure
Colucci WS
http://www.uptodate.com/contents/impact-of-anemia-in-patients-with-heart-failure
UpToDate, Wolters Kluwer Health - 2013-03-19

Authored Content

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure — NEJMMay 1996

Press Mentions

Mitochondria Studies Critical to Search for Heart Failure CureOctober 2nd, 2019

Grant Support

Oxidative Stress In Myocardial Remodeling And FailureNational Heart, Lung, And Blood Institute2001–2011
Mechanisms Of Oxidant Signaling In Post-Mi RemodelingNational Heart, Lung, And Blood Institute2004–2007
Action - A CHF Trial Investigating Outcomes Of ExerciseNational Heart, Lung, And Blood Institute2004–2007
Myocaridal Remodeling By Hemodynamic OverloadNational Heart, Lung, And Blood Institute2000–2002
NO &02-In Postmyocardial Infarction Remodeling &FaNational Heart, Lung, And Blood Institute1998–2002